Mesa Laboratories CAO Crennen Lyndsey Elizabeth Buys Company Shares
The CAO of Mesa Laboratories, Crennen Lyndsey Elizabeth, acquired 263 shares, valued at $25,011, on June 18.
Key Points
- Crennen Lyndsey Elizabeth, CAO of Mesa Laboratories, purchased 263 shares at $95.10 each, totaling $25,011, on June 18, 2026.
- Mesa Laboratories, Inc. has a market cap of $515.1 million, a P/E ratio of 77.05, and trades between $55.45 and $113.99 over 52 weeks.
- Institutional investors like Long Path Partners and Boston Partners have recently increased their positions in Mesa Laboratories.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Crennen Lyndsey Elizabeth, the Chief Accounting Officer (CAO) of Mesa Laboratories, Inc. (NasdaqGS: MLAB), recently acquired additional shares in the company. On June 18, 2026, she purchased 263 shares at an average price of $95.10 each, for a total transaction value of $25,011. This purchase was not part of a pre-planned trading program.
Other Institutional Activity in Mesa Laboratories
Institutional investors have shown varied interest in Mesa Laboratories. Long Path Partners LP significantly increased its holdings by 178,360 shares, bringing its total to 405,583 shares valued at approximately $35.9 million, reflecting a 78.5% increase. Boston Partners also grew its stake, adding 55,335 shares to reach a total of 268,711 shares worth around $23.8 million, marking a 25.9% increase. Meanwhile, BlackRock, Inc. slightly reduced its position by 4,815 shares, now holding 393,851 shares valued at $34.8 million, a 1.2% decrease. Select Equity Group, L.P. increased its holdings by 29,450 shares to 235,885 shares, valued at $20.9 million, a 14.3% increase. Vanguard Capital Management LLC opened a new position with 232,643 shares valued at $20.6 million.
Mesa Laboratories, Inc. Stock Down 27.7%
Shares of Mesa Laboratories, Inc. traded near $93.23 on Tuesday. The company, which operates in the technology sector, specifically in scientific and technical instruments, has a market capitalization of $515.1 million. Its P/E ratio stands at 77.05, with a forward P/E of 7.60, and it has a beta of 0.927. Over the past 52 weeks, the stock has ranged from a low of $55.45 to a high of $113.99. The stock's 50-day moving average is $101.99, and its 200-day moving average is $84.97. Mesa Laboratories maintains a current ratio of 1.717 and a quick ratio of 1.174, with a debt-to-equity ratio of 90.65.
$MLAB stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its recent earnings report, Mesa Laboratories posted revenue of $249.1 million, reflecting a growth rate of 2.6%. The company's earnings per share (EPS) was reported at $1.21. Mesa Laboratories achieved a net margin of 2.69% and a return on equity (ROE) of 3.88%. The next earnings release is scheduled for August 5, 2026.
Dividend
Mesa Laboratories pays an annual dividend of $0.64 per share, yielding 0.67%. The company's dividend payout ratio is 52.89%.
Insider Buying and Selling at Mesa Laboratories, Inc.
On June 18, 2026, in addition to Crennen Lyndsey Elizabeth's purchase, CFO John Sakys also bought 2,282 shares at $95.10 each. On the same day, SVP Operations Brian David Archbold acquired 1,859 shares at the same price. Following these transactions, on June 22, 2026, Crennen Lyndsey Elizabeth, John Sakys, and Brian David Archbold sold shares at $89.50 each.
Analysts Set New Price Targets
Analyst activity around Mesa Laboratories includes Wells Fargo maintaining a "hold" rating with a $94.00 price target as of February 4, 2026. The consensus among analysts is a mean price target of $112.00, based on two opinions.
About Mesa Laboratories
Mesa Laboratories, Inc. is a technology company based in Lakewood, Colorado. It designs and manufactures life sciences tools and quality control products. The company's offerings include sterilization and disinfection control, clinical genomics with genetic analysis tools, biopharmaceutical development systems, and calibration solutions for various industries. Mesa Laboratories operates globally, serving sectors like pharmaceuticals and healthcare, and is led by CEO Dr. Siddhartha Chandrakant Kadia.
Bottom Line
The recent insider buying activity by Mesa Laboratories' CAO, along with other executive transactions, highlights ongoing interest in the company's stock. With a diverse product range and a global presence, Mesa Laboratories remains a key player in the technology sector. Investors often track such insider activities for potential insights, though it's important to remember that these actions do not necessarily predict future stock performance.
Get Mesa Laboratories, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MLAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.